- $20.09m
- $16.35m
- $14.16m
- 55
- 38
- 92
- 66
Annual income statement for Nephros, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.56 | 10.2 | 9.97 | 14.2 | 14.2 |
| Cost of Revenue | |||||
| Gross Profit | 4.91 | 5.63 | 4.73 | 8.4 | 8.72 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12.8 | 13 | 14.3 | 15.8 | 14.2 |
| Operating Profit | -4.28 | -2.77 | -4.33 | -1.59 | 0.006 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.53 | -2.78 | -4.28 | -1.57 | 0.089 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.53 | -2.78 | -4.28 | -1.57 | 0.074 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -4.77 | -4.11 | -7.38 | -1.57 | 0.074 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.77 | -4.11 | -7.38 | -1.57 | 0.074 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.525 | -0.35 | -0.442 | -0.152 | 0.007 |